Precision Medicine

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

A new FDA approval for an EGFR-mutated lung cancer therapy cuts treatment from hours to minutes, offering new hope and convenience for thousands of patients.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.